merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Because Lilly’s vials are FDA‑approved and subject to regulatory oversight, offering a safer alternative</answer>
<question_number>2</question_number>
<answer>By using LillyDirect to sell FDA‑approved vials directly to patients, bypassing third‑party telehealth compounders and undercutting them on price</answer>
<question_number>3</question_number>
<answer>Lack of FDA oversight leading to safety and quality concerns</answer>
<question_number>4</question_number>
<answer>To undercut compounding pharmacies and reclaim customers by offering a more affordable alternative, even at the expense of pen sales</answer>
<question_number>5</question_number>
<answer>Being on the FDA’s shortage list legally permits compounding; removing tirzepatide from the list undermines compounders’ legal basis</answer>
<question_number>6</question_number>
<answer>It exemplifies the trend of manufacturers bypassing intermediaries to sell directly to consumers with transparent pricing</answer>
<question_number>7</question_number>
<answer>Medicare beneficiaries may self‑pay for the vials, exposing older patients to risks without insurance coverage</answer>
<question_number>8</question_number>
<answer>It highlights that FDA‑approved vials are safer, undermining confidence in compounded tirzepatide</answer>
<question_number>9</question_number>
<answer>Being listed as “in shortage” by the FDA</answer>
<question_number>10</question_number>
<answer>Signaling a willingness to undercut compounding pharmacies on price by offering cheaper vials</answer>